Comparison: Wegovy vs Zepbound
Both are reviewed at American Telehealth Review against published clinical evidence and FDA labeling.
Key differentiators
- Active ingredient: Wegovy is semaglutide (Novo Nordisk); Zepbound is tirzepatide (Eli Lilly).
- Mechanism: Wegovy GLP-1; Zepbound dual GLP-1/GIP.
- Weight loss: tirzepatide trended higher in SURPASS-2 (vs semaglutide 1 mg).
- CV indication: Wegovy has FDA-approved CV risk reduction; Zepbound has FDA-approved OSA indication.